Search Medical Condition
Please enter condition
Please choose location

Villejuif Cedex, France Clinical Trials

A listing of Villejuif Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (466) clinical trials

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

This is a multinational, multicenter, non-interventional (observational) and prospective study. European countries where vandetanib is on the market will participate in the study. This study is being conducted to fulfil the specific obligation post-authorisation measure for the conditional marketing authorisation. It is carried on to confirm in real life conditions ...

Phase N/A

0.0 miles

Learn More »

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

This study will consist of 3 phases: Prerandomization, Randomization, and a Follow-up Phase. The Prerandomization Phase includes one Screening Visit that will take place from Day -14 through Day -1; the Randomization Phase includes the Baseline Period, Treatment Period, and Procedure Day Period (5 to 8 days after last dose ...

Phase

0.0 miles

Learn More »

Neoadjuvant Treatment for Advanced Rectal Carcinoma

Colorectal cancer is one of the most frequent cancers diagnosed in France. The average age of diagnosis in 2012 was 70 years old for men and 73 years for women, confirming that colorectal cancer is a disease of the elderly population. The literature concerning combined treatments of colorectal cancer in ...

Phase

0.0 miles

Learn More »

Inflammatory Breast Cancer (IBC) Registry

IBC: IBC is a rare but rapidly growing form of breast cancer. Currently, there are no known risk factors and biological features (such as in the genes) that researchers can use to help design better treatments for IBC. Study Participation: If you are diagnosed with IBC or the doctor believes ...

Phase N/A

0.0 miles

Learn More »

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) will have limited stage disease, now called stage I-IIIB (IASLC). The outcome of limited disease SCLC is still poor, with a median survival of 16 to 24 months with current forms of treatment and only 15-25% ...

Phase

0.0 miles

Learn More »

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients

Screening phase: New frozen biopsy or an archived frozen sample will be sent to the genomic plateforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing). Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions have been met ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET

STZ based chemotherapy, STZ-5FU, is the actual standard of care for advanced pancreatic Neuroendocrine tumours (pNETS) in the European Union. Everolimus has been recently approved for its use in advanced pNETs by the Food and Drug Administration (FDA) and in Europe by the European Medical Agency (EMA). A randomized study ...

Phase

0.0 miles

Learn More »